NCT07716345Not yet recruiting
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
A Prospective Study on Inter-Individual Tumor Heterogeneity Assessed by Three-Dimensional Magnetic Resonance Elastography for Predicting Response to Conversion Therapy in Patients With Liver Cancer
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing. Substantial variation exists among patients in their tumor response to the same conversion therapy regimen, and current pretreatment imaging assessment does not adequately capture this inter-individual variability. We hypothesize that baseline tumor viscoelastic parameters measured by three-dimensional magnetic resonance elastography (3D-MRE) differ substantially across patients, and that this inter-individual heterogeneity may be associated with differential response to conversion therapy. This study aims to prospectively evaluate the association between baseline 3D-MRE-derived tumor viscoelastic parameters and pathological response as well as surgical conversion outcomes across patients with liver cancer receiving conversion therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 10 Jul 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Oct 2029
- Lead sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07716345
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Oct 2026 to the primary completion date, 1 Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Uncontrolled ascites, hepatic encephalopathy, or variceal bleeding within 3 months prior to enrollment
- Other concurrent active malignancy
- Severe comorbidities precluding conversion therapy or surgery
Other illness
- Child-Pugh class C liver function (for patients with primary liver cancer)
Other
- Contraindication to MRI
- Pregnant or breastfeeding women
- Anticipated poor compliance with repeated MRE examinations or follow-up
Who the study is looking for
- Age 18-75 years
- Pathologically or radiologically confirmed diagnosis of initially unresectable liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis)
- Planned to receive conversion therapy with the intent of achieving surgical resectability
- Child-Pugh class A or B liver function (for patients with primary liver cancer)
- ECOG performance status 0-1
- At least one measurable lesion per RECIST 1.1
- Able to undergo 3D-MRE examination prior to conversion therapy
- Provision of signed and dated informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.